We describe here a streamlined procedure for targeting vector construction, which often is a limiting factor for gene targeting (knockout) technology. This procedure combines various highly ...

Gene therapies can correct diseases at their genetic core, but their success hinges on viral vector manufacturing. | Explore the tales of one emerging and one established company seeking contract ...

Recombinant adeno-associated virus (rAAV) is a promising vector for delivering therapeutic genes to patients with genetic disorders.

"The era of gene therapy for neuromuscular diseases has begun, and the complexity of these diseases requires us to constantly innovate to improve drug candidates targeting muscle.

While the traditional cloning workflow has been used in laboratories for decades, new techniques have emerged that allow for rapid assembly of multiple genetic fragments. The Electra Vector System ...

Vector BioMed has developed a technology platform for designing and manufacturing the lentiviruses used to deliver cell and gene therapies. The startup is launching as the field continues to ...

Charles River launches nAAVigation Vector Platform, with the capability to reduce viral vector gene therapy program timelines to GMP by 55%.

Versant Ventures has committed $30 million to improve gene delivery. By pumping the cash into Vector BioPharma, the VC is aiming to address the limitations of existing systems such as the cap on ...

Versant Ventures today announced the debut of Vector BioPharma AG, a biopharmaceutical company developing a precision gene delivery platform that is d ...

Astellas paves backloaded biobucks deal to test 4DMT's eye disease gene therapy vector By Annalee Armstrong Jul 10, 2023 7:30pm Astellas Pharma 4D Molecular Therapeutics eye diseases Cell & Gene ...

Structural Group, Inc. (SGI) today announced that it has acquired Vector Construction / Restoration (Vector), which includes nine (9) branch locations in the United States and Canada.

Vector BioPharma has launched from the biotech startup incubator of Versant Ventures, which is backing the company with a $30 million Series A financing. Vector is developing virus-like particles ...